| Name | Title | Contact Details |
|---|---|---|
Lisa Wolf |
Interim CFO | Profile |
Sanjay Ahuja |
Senior Vice President, Quality Assurance and Regulatory Affairs | Profile |
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
Pharos Innovations is a Northfield, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Roselani Place is a Kahului, HI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Pharma Network is a Montvale, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Nodality is an innovative personalized medicine company focused on improving the efficiency of drug development for therapeutics as well as generating highly predictive companion diagnostics to improve patient care.